Greenwich LifeSciences (GLSI) Total Current Liabilities (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Total Current Liabilities data on file, last reported at $5.8 million in Q4 2025.

• Quarterly Total Current Liabilities rose 82.87% year-over-year to $5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 82.87% YoY) and the FY2025 annual result came in at $5.8 million, up 82.87% from the prior year.
• Total Current Liabilities improved to $5.8 million in Q4 2025, from $1.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $5.8 million in Q4 2025 to a low of $229134.0 in Q2 2022.
• A 5-year average of $1.0 million and a median of $422365.0 in 2021 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities sank 71.84% — and 2024, when it surged 981.89%.
• Tracing GLSI's Total Current Liabilities over 5 years: stood at $385172.0 in 2021, then sank by 31.74% to $262905.0 in 2022, then climbed by 11.98% to $294406.0 in 2023, then surged by 981.89% to $3.2 million in 2024, then surged by 82.87% to $5.8 million in 2025.
• The last three Total Current Liabilities figures came in at $5.8 million (Q4 2025), $1.6 million (Q3 2025), and $1.7 million (Q2 2025), per Business Quant data.